| Date | Title | |
| 11/20/09 | U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years) |  |
| 11/15/09 | Bristol-Myers Squibb Announces Split-Off of Mead Johnson | |
| 11/10/09 | Bristol-Myers Squibb to Present at Credit Suisse Healthcare Conference | |
| 11/10/09 | Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic | |
| 11/05/09 | FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients | |
| 10/31/09 | BARACLUDE(R) (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of Chronic Hepatitis B Patients with Evidence of Decompensated Cirrhosis | |
| 10/31/09 | Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C | |
| 10/29/09 | Bristol-Myers Squibb Donation to Benefit Students at The Pennington School and Beyond | |
| 10/26/09 | Medarex, Inc. Announces Expiration of Offer to Repurchase its 2.25% Convertible Senior Notes due May 15, 2011 | |
| 10/22/09 | Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter | |
| 10/20/09 | New Data Describe Safety of Subcutaneous Administration of ORENCIA(R) (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis | |
| 10/19/09 | ORENCIA(R) (abatacept) Demonstrated Sustained Clinical Response in a Study of Adult Patients with Moderate to Severe Early Rheumatoid Arthritis (Less Than Two Years Duration) | |
| 10/05/09 | ONGLYZATM (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes | |
| 10/05/09 | Study Finds That ONGLYZA(TM) (saxagliptin) When Added To Metformin Was Non-Inferior To JANUVIA (SITAGLIPTIN) When Added To Metformin In Reducing Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus | |
| 10/02/09 | Bristol-Myers Squibb to Announce Results for the Third Quarter of 2009 on October 22 | |
| 10/02/09 | Dapagliflozin Study Demonstrated Significantly Improved Glycemic Control and Weight Reduction in Type 2 Diabetes Patients Inadequately Controlled with Metformin | |
| 10/01/09 | New Data on Four Bristol-Myers Squibb Compounds to Be Presented at AASLD 2009 | |
| 09/24/09 | Medarex, Inc. Issues Notice of Change in Control to Holders of its Convertible Notes | |
| 09/23/09 | Data Presented from Two Phase 3 ERBITUX(R) Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress | |
| 09/15/09 | Bristol-Myers Squibb Company Announces Sale to Taisho Pharmaceutical Co Ltd., of Its OTC Assets in Asia Pacific (Excl. China & Japan) and Shares in PT Bristol-Myers Squibb Indonesia Tbk | |
| 09/11/09 | Bristol-Myers Squibb to Present at Morgan Stanley Global Healthcare Unplugged Conference | |
| 09/09/09 | Bristol-Myers Squibb Announces Dividend | |
| 09/03/09 | Bristol-Myers Squibb Announces Acceptance of Submission for Belatacept Biologic License Application | |
| 09/01/09 | Bristol-Myers Squibb Completes Acquisition of Medarex, Inc. | |
| 09/01/09 | Bristol-Myers Squibb Completes Tender Offer for Medarex, Inc. | |
| 08/30/09 | New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty | |
| 08/27/09 | Bristol-Myers Squibb Completes Initial Tender Offer for Medarex, Inc. with 87.7% of Shares Tendered; Announces Subsequent Offering Period | |
| 08/26/09 | Updated ORENCIA(R) (abatacept) Labeling Includes Data to Support Earlier Use in Adult Patients with Moderate to Severe Rheumatoid Arthritis | |
| 08/20/09 | Bristol-Myers Squibb Extends Tender Offer for Medarex, Inc. | |
| 08/20/09 | Bristol-Myers Squibb Announces Preliminary Court Approval of Derivative Settlement | |
| 08/12/09 | Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of Medarex, Inc. | |
| 07/31/09 | U.S. Food and Drug Administration Approves ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes Mellitus in Adults | |
| 07/28/09 | Bristol-Myers Squibb Begins Tender Offer to Acquire Medarex, Inc. | |
| 07/23/09 | Excellent Performance Highlights Second Quarter for Bristol-Myers Squibb | |
| 07/22/09 | Bristol-Myers Squibb to Acquire Medarex | |
| 07/20/09 | ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX(R) (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer | |
| 07/20/09 | Bristol-Myers Squibb's SECURE THE FUTURE Announces $1.3 Million in New Grants to Enhance Community-Based HIV/AIDS Care and Support in Africa | |
| 07/09/09 | Bristol-Myers Squibb to Announce Results for the Second Quarter and First Six Months of 2009 on July 23 | |
| 07/06/09 | New Online Resource Launches For Patients With Chronic Myeloid Leukemia | |
| 06/25/09 | ONGLYZA(TM) (Saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes | |
| 06/12/09 | ORENCIA(R) (abatacept) DEMONSTRATES CONSISTENT SAFETY AND EFFECTIVENESS OVER 7 YEARS | |
| 06/10/09 | Bristol-Myers Squibb Announces Dividend | |
| 06/10/09 | Bristol-Myers Squibb to Present at Goldman Sachs Global Healthcare Conference | |
| 06/06/09 | Interim Analysis of Long-Term Data with ONGLYZA(TM) (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Presented at ADA Annual Scientific Sessions | |
| 06/06/09 | Dapagliflozin Study Demonstrated Improved Glycemic Control In Type 2 Diabetes Patients Treated With High Doses of Insulin and Common Oral Anti-Diabetic Medicines | |
| 05/31/09 | Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg) | |
| 05/28/09 | First Phase III Data on Innovative Compound for Solid Organ Transplantation To be Featured at American Transplant Congress | |
| 05/26/09 | FDA Grants Full Approval for SPRYCEL(R) (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec(R)* | |
| 05/26/09 | Bristol-Myers Squibb to Present at Bernstein Strategic Decisions Conference | |
| 05/22/09 | Bristol-Myers Squibb Welcomes "Help is Here Express" to New Brunswick | |
| 05/18/09 | Bristol-Myers Squibb to Present at Deutsche Bank Healthcare Conference | |
| 05/14/09 | SPRYCEL(R) (Dasatinib) Shows Potential as Treatment for Prostate Cancer | |
| 05/12/09 | Bristol-Myers Squibb to Present at Bank of America and Merrill Lynch Health Care Conference | |
| 05/05/09 | Bristol-Myers Squibb to Present at Bernstein Pharmaceutical Emerging Markets Conference | |
| 04/29/09 | Bristol-Myers Squibb Invites Public to Listen to Webcast of 2009 Annual Meeting | |
| 04/28/09 | Bristol-Myers Squibb Reports Excellent First Quarter Financial Results; Delivers on Two Significant Strategic Initiatives | |
| 04/27/09 | Bristol-Myers Squibb Announces Call for Entries for the 2009 REYATAZ(R) (atazanavir sulfate) "Fight HIV Your Way" Contest | |
| 04/24/09 | Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C | |
| 04/23/09 | U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA(TM) (saxagliptin) New Drug Application | |
| 04/20/09 | Bristol-Myers Squibb to Announce Results for the First Quarter of 2009 on April 28 | |
| 04/06/09 | Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY(R) and Establishment of an Oncology Collaboration with Otsuka | |
| 04/01/09 | ONGLYZA(TM) (saxagliptin) Cardiovascular Profile Acceptable According to FDA Advisory Committee | |
| 03/31/09 | Plavix((R)) Plus Aspirin More Effective Than Aspirin Alone in Preventing Major Vascular Events in Patients with Atrial Fibrillation Who Cannot Take Oral Anticoagulants | |
| 03/31/09 | Plavix® Plus Aspirin More Effective Than Aspirin Alone in Preventing Major Vascular Events in Patients with Atrial Fibrillation Who Cannot Take Oral Anticoagulants | |
| 03/27/09 | Dapagliflozin Clinical Trial Results Indicate Improvement In Key Glycemic Measures In Treatment-Naive Type 2 Diabetes Patients | |
| 03/09/09 | Bristol-Myers Squibb to Present at Healthcare Conference | |
| 03/04/09 | Bristol-Myers Squibb Enters Global Collaboration with Nissan Chemical and Teijin Pharma on Novel Atrial Fibrillation Compound | |
| 03/03/09 | Bristol-Myers Squibb Announces Dividend | |
| 03/03/09 | Bristol-Myers Squibb Announces Organizational Changes; Names Four to Company's Executive Committee | |
| 03/02/09 | ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S. | |
| 02/13/09 | Bristol-Myers Squibb Foundation Announces Funding of More Than $1.17 Million to Bridge Gaps in Hepatitis C Awareness, Prevention and Care in China, India and Taiwan | |
| 02/11/09 | Bristol-Myers Squibb Statement on Mead Johnson Nutrition Company IPO | |
| 01/27/09 | Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb | |
| 01/23/09 | ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R) | |
| 01/16/09 | Bristol-Myers Squibb To Announce Results For The Fourth Quarter And Full Year Of 2008 On January 27 | |
| 01/13/09 | Bristol-Myers Squibb to Present at Healthcare Conference | |
| 01/12/09 | Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound | |
| 01/08/09 | Howard Feldman Joins Bristol-Myers Squibb as Vice President and Therapeutic Area Head, Global Clinical Research, Neuroscience | |
